178 related articles for article (PubMed ID: 25888978)
1. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
Makker V; Filiaci VL; Chen LM; Darus CJ; Kendrick JE; Sutton G; Moxley K; Aghajanian C
Gynecol Oncol; 2015 Jul; 138(1):24-9. PubMed ID: 25888978
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Burger RA; Deng W; Makker V; Collins Y; Gray H; Debernardo R; Martin LP; Aghajanian C
Gynecol Oncol; 2018 Sep; 150(3):466-470. PubMed ID: 30041929
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Posner MR; Wirth LJ; Saba NF; Cohen RB; Popa EC; Argiris A; Grossmann KF; Sukari A; Wilson D; Zhang X; Sun J; Glasser C; Attie KM; Sherman ML; Pandya SS; Weiss J
Cancer; 2016 Dec; 122(23):3641-3649. PubMed ID: 27648727
[TBL] [Abstract][Full Text] [Related]
4. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER
Cancer; 2019 Jul; 125(14):2400-2408. PubMed ID: 30951193
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
Bendell JC; Gordon MS; Hurwitz HI; Jones SF; Mendelson DS; Blobe GC; Agarwal N; Condon CH; Wilson D; Pearsall AE; Yang Y; McClure T; Attie KM; Sherman ML; Sharma S
Clin Cancer Res; 2014 Jan; 20(2):480-9. PubMed ID: 24173543
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Miksad RA; Tejani MA; Williamson S; Gutierrez ME; Olowokure OO; Sharma MR; El Dika I; Sherman ML; Pandya SS
Oncologist; 2019 Feb; 24(2):161-e70. PubMed ID: 30352941
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
Moore KN; Sill MW; Tenney ME; Darus CJ; Griffin D; Werner TL; Rose PG; Behrens R
Gynecol Oncol; 2015 Sep; 138(3):513-8. PubMed ID: 26171911
[TBL] [Abstract][Full Text] [Related]
8. The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Voss MH; Bhatt RS; Plimack ER; Rini BI; Alter RS; Beck JT; Wilson D; Zhang X; Mutyaba M; Glasser C; Attie KM; Sherman ML; Pandya SS; Atkins MB
Clin Cancer Res; 2017 Jul; 23(14):3557-3565. PubMed ID: 28031424
[No Abstract] [Full Text] [Related]
9. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
[TBL] [Abstract][Full Text] [Related]
11. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
[TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
[TBL] [Abstract][Full Text] [Related]
15. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL; Sill MW; Lankes HA; Fader AN; Finkler NJ; Hoffman JS; Rose PG; Sutton GP; Drescher CW; McMeekin DS; Hu W; Deavers M; Godwin AK; Alpaugh RK; Sood AK
Gynecol Oncol; 2012 Dec; 127(3):538-43. PubMed ID: 22922531
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
[TBL] [Abstract][Full Text] [Related]
17. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Dizon DS; Sill MW; Schilder JM; McGonigle KF; Rahman Z; Miller DS; Mutch DG; Leslie KK
Gynecol Oncol; 2014 Dec; 135(3):441-5. PubMed ID: 25312396
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
[TBL] [Abstract][Full Text] [Related]
19. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Chan JK; Brady W; Monk BJ; Brown J; Shahin MS; Rose PG; Kim JH; Secord AA; Walker JL; Gershenson DM
Gynecol Oncol; 2018 Aug; 150(2):247-252. PubMed ID: 29921512
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
